Table 3.

Studies on clinical efficacy of CBD-based products in the treatment of epilepsy in dogs.

Study design	Treatment	Results	References
Randomized placebo-controlled, double-blinded clinical trial to assess the effect of using a CBD-infused hemp oil in addition to conventional antiepileptic treatment on seizure frequency in 26 dogs with idiopathic epilepsy.	2.5 mg/kg of CBD oil orally twice daily for 12 weeks.	Compared with the placebo group, dogs in the CBD group had a significant reduction in seizure frequency (median change, 33%). However, the proportion of dogs considered responders to treatment (≥ 50% decrease in seizure activity) was similar between groups.	(67)
Case report of three dogs with suspected epilepsy, each one treated with a different dose of a CBD-predominant full-spectrum hemp oil.	0.51 mg/kg of CBD for the first dog, 1.24–1.25 mg/kg for the second dog, and 5 mg/kg for the third dog, given orally twice daily for 8 weeks.	Considerable reduction in epileptic seizures frequency and improvement of other signs (i.e., undesirable behavior) in one dog, slight improvement of seizure intensity in another, and no response to therapy in the third, as reported by the owners.	(69)
Randomized, controlled-placebo, cross-over study to examine the efficacy of a CBD and CBDA-rich hemp product for the treatment of refractory epileptic seizures in 14 dogs.	2 mg/kg of CBD orally twice daily for 12 weeks.	Statistically significant reduction in epileptic seizure frequency, as well as number of epileptic seizure days (the number of dogs with a 50% reduction in epileptic activity while on treatment were 6/14, whereas 0/14 had reductions of 50% or greater while on the placebo).	(68)